Standard BioTools Inc. (LAB)
LAB Stock Price Chart
Explore Standard BioTools Inc. interactive price chart. Choose custom timeframes to analyze LAB price movements and trends.
LAB Company Profile
Discover essential business fundamentals and corporate details for Standard BioTools Inc. (LAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
10 Feb 2011
Employees
814.00
Website
https://www.fluidigm.comCEO
Michael Egholm
Description
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
LAB Financial Timeline
Browse a chronological timeline of Standard BioTools Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.02, while revenue estimate is $18.00M.
Earnings released on 11 Aug 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $21.76M , missing expectations by -46.75%.
Earnings released on 6 May 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $40.80M , beating expectations by +3.98%.
Earnings released on 26 Feb 2025
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $46.72M , beating expectations by +8.56%.
Earnings released on 30 Oct 2024
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $44.97M , beating expectations by +4.50%.
Earnings released on 31 Jul 2024
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $37.21M , missing expectations by -9.92%.
Earnings released on 8 May 2024
EPS came in at -$0.23 falling short of the estimated -$0.09 by -155.56%, while revenue for the quarter reached $45.54M , missing expectations by -1.01%.
Earnings released on 28 Feb 2024
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $28.19M , beating expectations by +13.20%.
Earnings released on 7 Nov 2023
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $25.37M , beating expectations by +7.49%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.21 by +33.33%, while revenue for the quarter reached $27.67M , beating expectations by +14.32%.
Earnings released on 9 May 2023
EPS came in at -$0.11 falling short of the estimated -$0.06 by -98.77%, while revenue for the quarter reached $25.12M , missing expectations by -11.43%.
Earnings released on 14 Feb 2023
EPS came in at -$0.19 falling short of the estimated -$0.11 by -72.73%, while revenue for the quarter reached $27.02M , missing expectations by -28.89%.
Earnings released on 8 Nov 2022
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%, while revenue for the quarter reached $25.65M , missing expectations by -17.14%.
Earnings released on 8 Aug 2022
EPS came in at -$0.33 falling short of the estimated -$0.13 by -153.85%, while revenue for the quarter reached $18.78M , missing expectations by -36.95%.
Earnings released on 5 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.15 by -66.67%, while revenue for the quarter reached $26.50M , beating expectations by +3.33%.
Earnings released on 17 Feb 2022
EPS came in at -$0.12 surpassing the estimated -$0.28 by +57.14%, while revenue for the quarter reached $38.27M , beating expectations by +17.11%.
Earnings released on 8 Nov 2021
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%, while revenue for the quarter reached $28.50M .
Earnings released on 5 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.19 by -21.05%, while revenue for the quarter reached $31.02M .
Earnings released on 6 May 2021
EPS came in at -$0.25 falling short of the estimated -$0.14 by -78.57%, while revenue for the quarter reached $32.79M .
Earnings released on 10 Feb 2021
EPS came in at -$0.24 falling short of the estimated -$0.07 by -242.86%, while revenue for the quarter reached $44.61M .
Earnings released on 5 Nov 2020
EPS came in at -$0.08 surpassing the estimated -$0.20 by +60.00%, while revenue for the quarter reached $39.86M .
LAB Stock Performance
Access detailed LAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.